Evidence map›Paper›PMID 38606823›Full record

ArticleJournal of gynecologic oncology2024

SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma.

Yalong Deng, Lu Zhang, Changyuan Dai, Yan Xu, Qiyu Gan, Jingxin Cheng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yalong DengDepartment of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0009-0001-3791-3220
Lu ZhangDepartment of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-4583-7328
Changyuan DaiDepartment of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0009-0000-5069-9380
Yan XuDepartment of Pathology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-9144-9094
Qiyu GanDepartment of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-0254-5587
Jingxin ChengDepartment of Gynecology and Obstetrics, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-1608-7126
Shanghai East Hospital · CN

Funding

Natural Science Foundation of Jiangxi Province 20202ACB206006NNSFC 82260587Top-level Clinical Discipline Project of Shanghai Pudong PWYgf2021-07
6 · The paper itself

Abstract

objectiveSignaling lymphocytic activation molecule family members (SLAMFs) play a critical role in immune regulation of malignancies. This study aims to investigate the prognostic value and function of SLAMFs in ovarian cancer (OC).

methodsThe expression analysis of SLAMFs was conducted based on The Cancer Genome Atlas Ovarian Cancer Collection (TCGA-OV) and Gene Expression Omnibus (GEO) databases. Immunohistochemistry (IHC) was further performed on tissue arrays (n=98) to determine the expression of SLAMF7. Kaplan-Meier plotter and multivariate Cox regression model were used to evaluate the correlation of SLAMF7 expression with survival outcomes of patients. The molecular function of SLAMF7 in OC was further investigated using Gene Set Enrichment Analysis (GSEA).

resultsSLAMF7 mRNA expression were significantly upregulated in OC tumor tissue compared to normal tissue. IHC revealed that SLAMF7 expression was located in the interstitial parts of tumor tissue, and higher SLAMF7 expression was associated with favorable survival outcomes. GSEA demonstrated that SLAMF7 is involved immune-related pathways. Further analysis showed that SLAMF7 had a strong correlation with the T cell-specific biomarker (CD3) but not with the B cell (CD19, CD22, and CD23) and natural killer cell-specific biomarkers (CD85C, CD336, and CD337). Furthermore, IHC analysis confirmed that SLAMF7 was expressed in tumor-infiltrating T cells, and the IHC score of SLAMF7 was positively correlated with CD3 (r=0.85, p<0.001).

conclusionSLAMF7 is expressed in the interstitial components of clinical OC tissue, and higher SLAMF7 expression indicated a favorable prognosis for patients with OC. Additionally, SLAMF7 is involved in T-cell immune infiltration in OC.

Indexed as

Lymphocytes, Tumor-InfiltratingOvarian NeoplasmsSignaling Lymphocytic Activation Molecule FamilyAdultAgedBiomarkers, TumorCystadenocarcinoma, SerousFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedPrognosisUp-RegulationBiomarkers, TumorSignaling Lymphocytic Activation Molecule FamilySLAMF7 protein, humanOvary CancerPrognosisSLAMF7 ProteinTumor Immune

Identifiers

PMID38606823
PMCPMC11543254
OpenAlexW4394583835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.